Findings

What do systematic reviews say?

2,536 questions · 2,637 findings · 315 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 608 · 23.1%GRADE not reported 488 · 18.5%Very low 688 · 26.1%Low 540 · 20.5%Moderate 249 · 9.4%High 64 · 2.4%

Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg

Clinician's assessment of improvement of hirsutism Ferriman‐Gallwey score Scale from: 0 to 36 · women with hirsutism

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 40 participants
Very low

Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg

Change in serum androgen levels · women with hirsutism

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 40 participants
Moderate

Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg

Change in BMI ‐ not measured · women with hirsutism

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg

Improvement of other clinical signs of hyperandrogenism ‐ not measured · women with hirsutism

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Finasteride 5 mg vs spironolactone 100 mg

Participant‐reported improvement of hirsutism 4‐point Likert scale · women with hirsutism

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 34 participants
Low

Finasteride 5 mg vs spironolactone 100 mg

Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Finasteride 5 mg vs spironolactone 100 mg

Proportion of participants who reported an adverse event · women with hirsutism

Finasteride 5 mg showed no clear difference in proportion of participants who reported an adverse event compared with spironolactone 100 mg (moderate certainty).

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
RR 0.2 [0.03, 1.41]
1 study · 20 participants
Moderate

Finasteride 5 mg vs spironolactone 100 mg

Clinician's assessment of improvement of hirsutism Ferriman‐Gallwey score Scale from: 0 to 36 · women with hirsutism

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 34 participants
Low

Finasteride 5 mg vs spironolactone 100 mg

Change in serum androgen levels · women with hirsutism

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 34 participants
Low

Finasteride 5 mg vs spironolactone 100 mg

Change in BMI ‐ not measured · women with hirsutism

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Finasteride 5 mg vs spironolactone 100 mg

Improvement of other clinical signs of hyperandrogenism ‐ not measured · women with hirsutism

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intermittent oral vs oral calcitriol

Fall in PTH · patients with bone disease in children with chronic kidney disease

Intermittent oral showed no clear difference in fall in PTH compared with daily oral calcitriol (moderate certainty).

2 findings from 1 review

Interventions for bone disease in children with chronic kidney disease 2010 · Cochrane Headline outcomes only
RR 0.88 [0.65, 1.19]
1 study · 59 participants
Moderate
Interventions for bone disease in children with chronic kidney disease 2010 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 83 participants
Moderate

Intermittent oral vs oral calcitriol

Kidney function · patients with bone disease in children with chronic kidney disease

1 finding from 1 review

Interventions for bone disease in children with chronic kidney disease 2010 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 83 participants
Moderate

Intermittent oral vs oral calcitriol

Adverse events ‐ Calcium > 11.5 mg/dL · patients with bone disease in children with chronic kidney disease

1 finding from 1 review

Interventions for bone disease in children with chronic kidney disease 2010 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 80 participants
Moderate

Intermittent oral vs oral calcitriol

Adverse events ‐ Phosphorus level > 7.5 mg/dL · patients with bone disease in children with chronic kidney disease

1 finding from 1 review

Interventions for bone disease in children with chronic kidney disease 2010 · Cochrane Headline outcomes only
no estimate extracted
1 study · 59 participants
Low

Vitamin D vs placebo/no treatment

PTH · patients with bone disease in children with chronic kidney disease

1 finding from 1 review

Interventions for bone disease in children with chronic kidney disease 2010 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Low

Vitamin D vs placebo/no treatment

Number without 30% fall in PTH on two occasions · patients with bone disease in children with chronic kidney disease

Vitamin D preparations may leads to lower number without 30% fall in PTH on two occasions compared with placebo/no treatment (low certainty).

1 finding from 1 review

Interventions for bone disease in children with chronic kidney disease 2010 · Cochrane Headline outcomes only
RR 0.6 [0.4, 0.89]
2 studies · 76 participants
Low

Vitamin D vs placebo/no treatment

Hypercalcaemia · patients with bone disease in children with chronic kidney disease

1 finding from 1 review

Interventions for bone disease in children with chronic kidney disease 2010 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 103 participants
Low

Vitamin D vs placebo/no treatment

Change in calcium‐phosphorus product mg(2)/dL(2) · patients with bone disease in children with chronic kidney disease

1 finding from 1 review

Interventions for bone disease in children with chronic kidney disease 2010 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 76 participants
Moderate

Calcitriol vs ergocalciferol

Height velocity equal to or greater than expected · patients with bone disease in children with chronic kidney disease

It is very uncertain whether calcitriol changes height velocity equal to or greater than expected compared with ergocalciferol (very low certainty).

1 finding from 1 review

Interventions for bone disease in children with chronic kidney disease 2010 · Cochrane Headline outcomes only
RR 0.22 [0.03, 1.53]
1 study · 15 participants
Very low